Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6253-6258

  Ng, Bruce ^a   Zakrzewski, Jan ^a   Warycha, Melanie ^a   Christos, Paul J ^a   Bajorin, Dean F ^c   Shapiro, Richard L ^a   Berman, Russell S ^a   Pavlick, Anna C ^a   Polsky, David ^a   Mazumdar, Madhu ^a   Montgomery, Anthony ^d   Liebes, Leonard ^a   Brooks, Peter C ^a,b   Osman, Iman ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; EPITOPE; PROTEIN HU177; UNCLASSIFIED DRUG; COLLAGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CANCER SIZE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BIOSYNTHESIS; BLOOD; CELL ADHESION; CHEMISTRY; COHORT ANALYSIS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY);

ADULT; AGED; AGED, 80 AND OVER; CELL ADHESION; COHORT STUDIES; COLLAGEN; COLLAGEN TYPE IV; EPITOPES; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 57649128000     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4992     Document Type: Article

References (30)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta (GA): 2007.
2. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-7.
3. Roth JM, Caunt M, Cretu A, et al. Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. Am J Pathol 2006;168:1576-86.
4. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200:448-64.
5. Xu J, Rodriguez D, Petitclerc E, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001;154:1069-79.
6. Clamp AR, Jayson GC. The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer 2005;93:967-72.
7. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65:3967-79.
8. Eder JP, Jr., Supko JG, Clark JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20:3772-84.
9. Hansma AH, Broxterman HJ, van der Horst I, et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann Oncol 2005;16:1695-701.
10. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20:3792-803.
11. Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24:3555-61.
12. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223-31.
13. Gagne PJ, Tihonov N, Li X, et al. Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion. Am J Pathol 2005;167:1349-59.
14. Cretu A, Roth JM, Caunt M, et al. Disruption of endothelial cell interactions with the novel HU177 cryptic collagen epitope inhibits angiogenesis. Clin Cancer Res 2007;13:3068-78.
15. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
16. Demierre MF, Chung C, Miller DR, et al. Early detection of thick melanomas in the United States: beware of the nodular subtype. Arch Dermatol 2005;141:745-50.
17. Chamberlain AJ, Fritschi L, Kelly JW. Nodular melanoma: patients' perceptions of presenting features and implications for earlier detection. J Am Acad Dermatol 2003;48:694-701.
18. Chamberlain AJ, Fritschi L, Giles GG, et al. Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol 2002;138:609-14.
19. Hanrahan PF, Hersey P, D'Este CA. Factors involved in presentation of older people with thick melanoma. Med J Aust 1998;169:410-4.
20. Kopf AW, Welkovich B, Frankel RE, et al. Thickness of malignant melanoma: global analysis of related factors. J Dermatol Surg Oncol 1987;13:345-90, 401-20.
21. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-78.
22. Golger A, Young DS, Ghazarian D, et al. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study. Arch Otolaryngol Head Neck Surg 2007;133:442-7.
23. Jaeger J, Koczan D, Thiesen HJ, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 2007;13:806-15.
24. Pavey SJ, Cummings MC, Whiteman DC, et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 2002;12:539-47.
25. Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 2005;125:575-9.
26. Giatromanolaki A, Sivridis E, Kouskoukis C, et al. Hypoxia-inducible factors 1α and 2α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003;13:493-501.
27. Becker JC, Kirkwood JM, Agarwala SS, et al. Molecularly targeted therapy for melanoma: current reality and future options. Cancer 2006;107:2317-27.
28. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20:3906-27.
29. Solti M, Berd D, Mastrangelo MJ, et al. A pilot study of low-dose thalidomide and interferon α-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res 2007;17:225-31.
30. Pavlick A, Liebes L, Brooks P. BAY 43-9006 (sorafenib-BAY) alters proliferation pathways and mutant specific-PCR (MS-PCR) improves detection of BRAF mutations in metastatic melanoma (MM). J Clin Oncol 2007;25:abstract 8534.